Last reviewed · How we verify

NCT06848270

Effectiveness of Early Intervention in Palliative Care for Acute Myeloid Leukemia Patients Comparing to Standard of Care

Not yet recruiting NA Last updated 27 February 2025
What this trial tests

NA trial testing Early palliative care integration in Palliative Care in 50 participants. Not yet recruiting.

Timeline
1 April 2025
Primary endpoint
31 July 2026
1 August 2026

Quick facts

Lead sponsorUniversidade do Porto
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposesupportive care
Enrollment50
Start date1 April 2025
Primary completion31 July 2026
Estimated completion1 August 2026
Sites1 location across Portugal

Drugs / interventions tested

Conditions studied

Sponsor

Universidade do Porto — full company profile →

Who can join

Under 70, any sex, with Palliative Care or Acute Myeloid Leukaemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Hemato-oncology patients undergoing intensive chemotherapy treatments experience different types of symptoms during and after treatments, which are often refractory to the established therapy. Physical symptoms such as pain, dyspnea, mucositis, insomnia, loss of appetite, constipation and diarrhea, among others, have a huge impact on quality of life, temporarily until symptomatic control, but also permanently with the development of anxiety, depression, long-term fatigue and post-traumatic stress. As recommended by ASCO (American Society of Clinical Oncology), the palliative approach to oncological diseases must be as early as possible and be part of the "standard of care". However, the lack of concrete data on this topic in the last decade served as a barrier to the early integration of this same care for hemato-oncology patients in its various areas. Palliative care presupposes global, interdisciplinary action, carried out by specific teams that must act in situations of incurable or serious illness, in an advanced and progressive phase. The potential benefits can be countless and of significant importance, from the impact on quality of life, symptomatic control, reduction of anxiety and depression and even the promotion of informed and conscious choices at the end of life as well as the reduction of aggressive strategies. used at this stage of the disease.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Early palliative care integration

Trials testing the same drug.

Other recruiting trials for Palliative Care

Currently open trials in the same condition.

Other Universidade do Porto trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06848270.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing